Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celltrion's Truxima First Biosimilar MAB In Oncology To Win EU Approval

Executive Summary

Celltrion's version of Roche’s MabThera (rituximab), Truxima, has become the first biosimilar anticancer to win marketing authorization in Europe.

You may also be interested in...



Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence

Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.

Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence

Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.

Celltrion's Herceptin Biosimilar One Step Closer To US FDA Approval

Following Oncologic Drugs Advisory Committee's recommendation for Mylan and Biocon's trastuzumab biosimilar, Celltrion and Teva's CT-P6 appear to be one of the next one in, but given the expiry of Herceptin patent in the US and other late stage trastuzumab biosimilar candidates, it could be anybody's game to launch their products first.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel